PSMD13 Human
Description
PSMD13 is fused to a 23 amino acid His-tag at N-terminus & purified by proprietary chromatographic techniques.
Product Specs
Product Science Overview
The Proteasome 26S Subunit, Non-ATPase 13 (PSMD13), also known as Rpn9 or p40.5, is a crucial component of the 26S proteasome complex in humans. This subunit plays a significant role in the ATP-dependent degradation of ubiquitinated proteins, which is essential for maintaining cellular homeostasis by removing misfolded, damaged, or unnecessary proteins .
The 26S proteasome is a large, multi-protein complex with a molecular mass of approximately 2000 kDa. It consists of a central 20S core proteasome and two 19S regulatory particles attached to either end of the core. The 20S core is composed of four rings of 28 non-identical subunits, while the 19S regulatory particles are divided into a base and a lid. The base contains six ATPase subunits and two non-ATPase subunits, and the lid contains up to ten non-ATPase subunits, including PSMD13 .
PSMD13 is involved in the regulation of the proteasome’s activity. The 26S proteasome plays a key role in various cellular processes, including:
- Protein Homeostasis: By degrading misfolded or damaged proteins, the proteasome prevents the accumulation of potentially toxic proteins that could impair cellular functions .
- Cell Cycle Progression: The proteasome regulates the levels of cyclins and other cell cycle-related proteins, ensuring proper cell cycle progression .
- Apoptosis: The degradation of pro-apoptotic and anti-apoptotic proteins by the proteasome influences the cell’s decision to undergo programmed cell death .
- DNA Damage Repair: The proteasome is involved in the degradation of proteins that participate in the DNA damage response, thereby facilitating the repair process .
Dysfunction or alterations in the proteasome system, including PSMD13, have been implicated in various diseases, such as cancer, neurodegenerative disorders, and autoimmune diseases. The proteasome’s role in degrading misfolded proteins is particularly relevant in neurodegenerative diseases like Alzheimer’s and Parkinson’s, where the accumulation of misfolded proteins is a hallmark .
Given its central role in protein degradation, the proteasome, and by extension PSMD13, is a target for therapeutic interventions. Proteasome inhibitors, such as bortezomib, are already used in the treatment of multiple myeloma and other cancers. Ongoing research aims to develop more specific inhibitors that can target particular subunits of the proteasome, potentially leading to more effective and less toxic treatments .
